Turn Therapeutics (NASDAQ:TTRX) Coverage Initiated at D. Boral Capital

Analysts at D. Boral Capital initiated coverage on shares of Turn Therapeutics (NASDAQ:TTRX) in a research report issued to clients and investors on Monday, MarketBeat reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. D. Boral Capital’s price objective indicates a potential upside of 191.97% from the stock’s previous close.

Turn Therapeutics Stock Performance

Shares of TTRX opened at $2.74 on Monday. Turn Therapeutics has a 1-year low of $2.57 and a 1-year high of $26.50. The company’s 50-day moving average is $3.58.

Turn Therapeutics (NASDAQ:TTRX) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.07) EPS for the quarter.

Insider Buying and Selling at Turn Therapeutics

In other news, Director Arthur F. Golden bought 9,868 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was bought at an average price of $3.44 per share, with a total value of $33,945.92. Following the acquisition, the director owned 60,602 shares of the company’s stock, valued at approximately $208,470.88. This represents a 19.45% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Abraham Chesed purchased 14,286 shares of the firm’s stock in a transaction on Thursday, October 23rd. The shares were acquired at an average cost of $4.60 per share, for a total transaction of $65,715.60. Following the completion of the acquisition, the insider owned 1,447,268 shares of the company’s stock, valued at approximately $6,657,432.80. This trade represents a 1.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 52,136 shares of company stock worth $183,463 over the last 90 days.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.